Brown & Brown heads into the week of April 28 with its stock down sharply and a wall of analyst target cuts arriving in the immediate aftermath of a disappointing earnings release.
The story this week is the Street's reaction to results. The pace of target reductions is striking — at least four firms lowered their numbers on April 29 alone. RBC Capital cut to $72 from $76, Wells Fargo trimmed to $69 from $72, and Keefe Bruyette & Woods moved to $72 from $74, all while holding their neutral-leaning ratings. The lone bull in the room, Truist Securities, kept its Buy rating but slashed the target to $90 from $100 — a meaningful concession. The broader trend running through April tells the same story: JPMorgan, Barclays, and Goldman Sachs all trimmed targets earlier in the month, in each case maintaining ratings but pulling numbers in. The consensus mean price target now stands at roughly $75, implying around 18% upside from the current $63.14 close — but that gap is a function of where the stock went rather than where the Street raised ambitions.
Short interest paints a quietly building picture. At 5.4% of the free float — roughly 18.5 million shares — the position is not extreme, but it has risen nearly 4% over the past week and about 2.5% over the past month. That puts it at a gentle but consistent upward drift since early April. Borrowing costs remain trivially low at 0.51% annually, and the lending market is nowhere near stressed. Availability is comfortable, with the borrow pool far from exhausted — the 52-week high on utilization was only 18.45%, and the current reading of roughly 15% has eased from where it was in late March. The short score has edged above 50 for the first time in recent sessions, but at 50.5 it reflects a neutral-to-slightly-cautious reading rather than an aggressive bear thesis. Shorts are adding quietly, not piling in.
Options positioning is relaxed. The put/call ratio at 0.37 is barely above its 20-day average of 0.36, and the z-score of 0.47 signals nothing unusual. For context, the 52-week high on the PCR was 0.95 — the current level is in the bottom third of the year's range, meaning options traders are not hedging for disaster. That stands in mild contrast to the equity selloff, which has taken BRO down 8.4% on the week and 17% year-to-date. The earnings reaction itself — a 4.2% single-day drop on April 27 — was sharper than the last quarterly print, which saw a modest 1.8% gain on the day.
The bull case remains grounded in structural tailwinds: pricing gains of 5-10% in casualty and commercial auto, the Specialty Distribution segment outpacing Retail, and exposure to the expanding Florida surplus-lines market which contributes more than a fifth of revenues. The bear case is harder to dismiss after this week's print — commercial property premiums fell 39% in Q4, total premiums dropped to $760 million from $1.3 billion the prior period, and lower investment income projections add further margin pressure into 2026. Neither the 13.6x PE nor the 11.1x EV/EBITDA look demanding for a franchise of this quality, but both multiples have compressed alongside the price this month.
On the institutional side, Capital Research added over 5 million shares in Q1, moving to a 6.7% stake — a notable commitment heading into what turned out to be a difficult quarter. Vanguard also added about 1.3 million shares. The family ownership through J. Brown remains anchored at around 11% and unchanged, providing a stable anchor but no fresh signal.
The next scheduled earnings call is May 6 — worth watching to see whether management's commentary on organic growth cadence and Florida market conditions shifts the analyst community's posture from "targets down, ratings held" toward anything more directional.
See the live data behind this article on ORTEX.
Open BRO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
